Blood Cancers and Monoclonal Proteins: Several Renal Mechanisms

Student Handouts and Nephrology Primer · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Use the protein pattern to choose the next test, then connect the renal lesion to the responsible clone.

Blood Cancers and Monoclonal Proteins: Several Renal Mechanisms. Full text follows below.
Download infographic (PNG) · Download Markdown · Read text version ·

Text version

Cast, deposit, or amyloid?

Light chains can obstruct/injure tubules as casts, deposit in basement membranes, or form amyloid fibrils. These mechanisms produce different renal syndromes; a monoclonal band alone cannot identify the lesion.

A dipstick can miss the clue

The urine dipstick mainly detects albumin. Substantial total urinary protein with relatively little albumin raises concern for light-chain or other nonalbumin protein. Compare ACR with total protein quantification.

Order complementary protein studies

Use serum free light chains with kidney/assay-aware interpretation, serum immunofixation, and urine immunofixation/electrophoresis as indicated. A negative serum electrophoresis alone does not exclude a pathogenic monoclonal protein.

Biopsy links clone and kidney

Renal pathology can distinguish cast nephropathy, monoclonal deposits, amyloid, or unrelated disease. Suspected amyloid must be confirmed and typed. A small clone can warrant clone-directed treatment when it causes MGRS.

AKI with suspected myeloma is urgent

Coordinate hematology and nephrology promptly. Assess volume, calcium, infection, nephrotoxins, and dialysis indications while addressing the clone; avoid delaying definitive assessment for an empiric extracorporeal light-chain-removal strategy.

Worked example

A patient has edema, heavy albuminuria, and a monoclonal protein. AL amyloid is possible, but the band does not prove it. Tissue confirmation and accurate typing determine whether treatment should target that clone.

Continue learning